Hyderabad Shines on as Vaccination Capital-KTR
Covaxin is a highly purified and inactivated two-dose SARS-CoV-2 vaccine
Hyderabad, Jan 3 (Maxim News): Minister for IT industries and Municipal Administration, KT Rama Rao said today that Hyderabad continues to shine on as the vaccination Capital of the country.
In a tweet, he expressed happiness over the Drugs Controller General of India giving it’s approval for use of Covaxin developed by the city-based Bharat Biotech, to treat Corona.
Many Congratulations to Dr. Krishna Ella, Suchitra Ella & the entire team of scientists @BharatBiotech on getting DCGI approval for Covaxin👍
Hyderabad continues to shines on as the vaccine capital because of the pursuit of excellence of scientists & innovative entrepreneurs
— KTR (@KTRTRS) January 3, 2021
Complimenting the company, KTR said: “many congratulations to Dr Krishna Yella, Suchitra Yella, and the entire team of scientists at the Bharat Biotech on getting DCGI approval for Covaxin.
Hyderabad continues to shine on as the vaccination capital because of the pursuit of excellence of scientists and innovative entrepreneurs”.
“Truly grateful for your belief in an indigenous technology and your persistent support,” replied Bharat Biotech.
Drug Controller General of India
It is to mention here that the Drug Controller General of India (DCGI) on Sunday granted permission for emergency use of Covaxin. This came a day after the emergency use authorisation (EUA) approval recommendation by the subject expert committee (SEC) of Central Drugs Standards Control Organization (CDSCO).
Covaxin, India’s indigenous Covid vaccine, has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
According to the company, Covaxin is a highly purified and inactivated two-dose SARS-CoV-2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses.
The phase III human clinical trials of Covaxin began in November. It is targeted for 26,000 volunteers across India. The company on Saturday announced that it enrolled 23,000 volunteers.
This is India’s first and only Phase III efficacy study for a Covid-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India.
Covaxin has been evaluated in approximately 1,000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer reviewed scientific journals.